“We found that, overall, segmental ureterectomy patients actually did better in terms of overall survival,” says Siv Venkat, MD, FRCSC.
In this video, Siv Venkat, MD, FRCSC, discusses the background and findings of the study, “Comparison of radical nephroureterectomy and segmental ureterectomy in upper tract urothelial carcinoma,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Venkat is a urologic oncology fellow at Weill Cornell Medicine and New York-Presbyterian Hospital in New York City, New York.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.